Treatment of Bacterial Vaginosis
For non-pregnant women with bacterial vaginosis, treat with metronidazole 500 mg orally twice daily for 7 days as first-line therapy, which provides the highest cure rates and is equally efficacious to other metronidazole regimens. 1
Recommended First-Line Regimens (Non-Pregnant Women)
The CDC guidelines establish three equally acceptable first-line options 1:
- Metronidazole 500 mg orally twice daily for 7 days (preferred for efficacy)
- Metronidazole gel 0.75%, one full applicator (5g) intravaginally once daily for 5 days
- Clindamycin cream 2%, one full applicator (5g) intravaginally at bedtime for 7 days
Important distinction: The oral metronidazole regimens are equally efficacious to each other, but vaginal clindamycin cream appears less efficacious than the metronidazole regimens 1. This makes oral metronidazole the optimal choice when compliance is expected.
Alternative Regimens (Lower Efficacy)
Use these only when first-line options are not tolerated 1:
- Metronidazole 2g orally as single dose (lower efficacy - 84% vs 95% cure rate) 2
- Clindamycin 300 mg orally twice daily for 7 days
- Clindamycin ovules 100g intravaginally once at bedtime for 3 days
Critical Patient Counseling Points
Metronidazole-specific warnings 1:
- Avoid alcohol during treatment and for 24 hours after completion (disulfiram-like reaction)
- Patients may experience mild-to-moderate GI upset and unpleasant metallic taste
Clindamycin-specific warnings 1:
- Oil-based formulations weaken latex condoms and diaphragms
- Refer to condom product labeling for additional information
Treatment in Pregnancy
All symptomatic pregnant women must be tested and treated due to associations with premature rupture of membranes, preterm labor, preterm birth, postpartum endometritis, and post-cesarean wound infections 1.
Pregnancy-Specific Regimens 1:
- Metronidazole 250 mg orally three times daily for 7 days
- OR Clindamycin 300 mg orally twice daily for 7 days
Critical pregnancy considerations:
- Use systemic (oral) therapy, NOT topical agents 1
- Evidence from three trials shows increased adverse events (prematurity, neonatal infections) after clindamycin cream use in pregnancy 1
- Multiple studies and meta-analyses show NO consistent association between metronidazole use in pregnancy and teratogenic/mutagenic effects 1, 3
- The older 1993 guideline contraindicated metronidazole in first trimester 2, but this has been superseded by newer evidence showing safety 1, 3
Recurrent BV Management
Recurrence is common (50-80% within one year) 4, 5, 6. For recurrent disease 1:
- Use another recommended treatment regimen from the first-line options
- No long-term maintenance regimen with any therapeutic agent is currently recommended by CDC guidelines
- Follow-up visits unnecessary if symptoms resolve
Recent evidence on partner treatment: The 2026 StepUp trial demonstrated that treating male partners with combined oral and topical antibiotics significantly reduces BV recurrence 7. The American College of Obstetricians and Gynecologists now advises partner therapy for recurrent BV 7, though this represents evolution beyond the CDC guidelines provided.
Special Populations
Allergy/Intolerance to Metronidazole 1:
- Clindamycin cream or oral clindamycin is preferred
- Metronidazole gel can be considered for patients who don't tolerate systemic metronidazole
- Never give metronidazole vaginally to patients allergic to oral metronidazole
Pre-Surgical Procedures 1:
Treatment of BV with metronidazole substantially reduces postabortion PID (10-75% reduction in post-operative infectious complications). Consider screening and treating women with BV before:
- Surgical abortion
- Hysterectomy
- (More data needed for other invasive procedures)
Partner Management
Routine treatment of sex partners is NOT recommended 1, 2. Clinical trials indicate that partner treatment does not affect the woman's response to therapy or likelihood of relapse/recurrence in the context of these older guidelines. However, this recommendation is evolving based on recent 2026 evidence 7.
Common Pitfalls to Avoid
- Don't use the single-dose metronidazole 2g regimen as first-line - it has significantly lower efficacy (84% vs 95%) 2
- Don't use topical agents in pregnancy - associated with worse outcomes 1
- Don't use lactobacilli douching - no data support non-vaginal lactobacilli or douching for BV treatment 1
- Don't schedule routine follow-up - unnecessary if symptoms resolve 1
- Don't assume metronidazole is teratogenic - this concern is outdated and not supported by human data 1, 3